• Proteus Digital Health

  Participated · Equity · Oct 2008

  Proteus Digital Health develops digital medicines combining an ingestible sensor, a wearable patch, mobile apps and data analytics to provide objective summaries of drug ingestion and physiologic data. Its flagship product, ABILIFY MYCITE, is an FDA‑approved drug‑device combination that pairs aripiprazole tablets embedded with an ingestible event marker, the MYCITE Patch, and a companion app and dashboards. The company holds more than 450 issued patents and has regulatory clearances in the U.S., European Union and China. Proteus plans to expand its portfolio by integrating its sensors with other therapies, develop next‑generation product features and sensor capabilities, and pursue broader commercialization and software integration. The expanded collaboration with Otsuka dedicates joint teams for commercial development, software integration and standardization, manufacturing and supply‑chain coordination. Proteus is privately held by investors that include Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka and ON Semiconductor. Proteus Discover combines an FDA-cleared ingestible sensor co-encapsulated with medications, a small wearable patch, patient and provider applications, and data analytics to record dosing times and physiologic metrics such as heart rate and activity. The ingestible sensor is described as the size of a grain of sand and, when taken, signals the patch which logs medication-taking and physiologic responses. The company currently markets a co-encapsulation model and is pursuing further FDA review for a panel of Digital Medicines with the sensor directly integrated into medications. Proteus plans to drive increased adoption of Proteus Discover by partnering with health system customers to demonstrate outcomes achievable with Digital Medicines. The company says the new capital will strengthen its balance sheet and provide funding to expand its Digital Medicine platform and commercial efforts. Proteus Digital Health develops digital medicines that integrate pharmaceuticals with ingestible sensors, wearable devices, mobile and cloud computing to provide the digital health feedback system. Its core products include ingestible sensors and wearable devices; Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for those devices. The company says its platform provides an unprecedented view into patients’ health choices and physiologic responses and enables new information-based business models. Proteus is privately held and headquartered in Redwood City, Calif., and is funded by institutional and strategic investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle and ON Semiconductor. The company completed a financing process in which it announced a $120 million first part on June 2 and then completed a second closing of its Series G financing raising over $172 million. Proteus intends to use the funding to advance manufacturing and commercialization of its digital medicines. Proteus Digital Health develops digital medicine products that combine tiny ingestible sensors, wearable sensor devices, and a digital health feedback system. The company's core product embeds a tiny sensor in pharmaceuticals that communicates medication-taking behavior and how a patient’s body is responding. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable sensor devices. Led by CEO Andrew Thompson, the company is working to define an innovative category of products, services and data systems called Digital Medicines. Financially, Proteus secured a $31.6M debt financing package whose proceeds will be used for working capital growth. The company is funded by investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and others. Proteus Digital Health develops Digital Medicines built around ingestible sensors and a digital health feedback system that communicates medication-taking behavior and physiologic response. Its core product set includes ingestible sensors and wearable devices plus data systems intended to enable new care paradigms and information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and ingestible sensor devices. The company says it aims to embed its technology into established products and services to accelerate its mission and change healthcare. Proteus completed a second closing of its Series F financing, raising $62.5 million in total. It is privately held and funded by investors including Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and others; the recent financing added corporate investor Oracle alongside Otsuka, Novartis and Sino Portfolio.

No current team members are available.